Discuz! Board

 找回密码
 立即注册
搜索
热搜: 活动 交友 discuz
查看: 8|回复: 0

全球十大医疗器械企业TOP 10!

[复制链接]

1万

主题

1万

帖子

5万

积分

管理员

Rank: 9Rank: 9Rank: 9

积分
58026
发表于 2020-10-14 13:29:33 | 显示全部楼层 |阅读模式

                    

                    

                    
                    
                    <section data-role="paragraph" data-color="rgb(182, 228, 253)" data-custom="rgb(182, 228, 253)"><section><section><section><section powered-by="gulangu"><section><section><section><section powered-by="gulangu"><section><section><section><section powered-by="gulangu"><section><section><section><section powered-by="gulangu"><section><section><section><section><p><p><img src="image/20201014/86b79d371e9862b01189f0252a03b2cd_1.png" /></p></p></section><section><section><span><strong></strong></span></section><p><span>医疗器械媒体报道先锋</span></p><p><span>分享专业医疗器械知识</span></p></section><section><section><section><span>关注</span></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section><p><br  /></p><p><span>来源:</span><span>医疗器械经销商联盟、大医疗整理</span></p><p><br  /></p><p><span>近日,国外权威的医疗器械第三方网站massdevice发布了《2019年全球医疗器械100强》榜单,该榜单根据2018财年营收统计。</span><span>该榜单显示,并购和扩张正在改变全球顶级医疗器械公司的排名。</span><br  /></p><p><br  /></p><p><span>总体来说,全球100强医疗器械公司最近一个财政年度的销售额为3975亿美元,比上一年增长了3.5%。</span><span>随着公司不断合并,小公司也在名单中垫底。</span><span>今年排名第100位的是RA医疗系统公司,年收入近630万美元。</span></p><p><br  /></p><p><span>以下是2019年全球十大医疗器械公司名单。</span><span>值得注意的是,除了排名前三的美敦力、强生、飞利浦、第八的丹纳赫,10强的其余排名均发生变化。</span></p><section data-tools="gulangu" data-id="95070"><section data-width="100%"><section><br  /></section><p><p><img src="image/20201014/75d3d33c6c038e33bbe7a0cefb84d4d9_2.jpg" /></p></p><section><section powered-by="gulangu"><section></section></section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><p><strong>No.10</strong></p></section></section></section></section><section><section powered-by="gulangu"><p><strong>EssilorLuxottica</strong></p></section></section></section><section powered-by="gulangu"><section><p><br  /></p><p>2018年收入:127.61亿美元</p><p>研发支出:22.45亿美元</p><p>员工:150000</p><p>员工平均收入:85075美元</p><p>财政年度结束:2018年12月31日</p><p>去年排名:15</p></section></section></section></section><section powered-by="gulangu"><section></section></section></section><section><br  /></section></section></section><p><span>EssilorLuxottica于去年10月与法国镜片专家Essilor和意大利眼镜制造商Luxottica合并后成立,以540亿欧元的价格成为全球最大的眼镜制造商。</span><span>通过并购从全球医疗器械企业第15位一举跃进十强席位。</span></p><p><br  /></p><p><span><strong><span>合并之后的EssilorLuxottica,拥有近15万名员工,综合报告年收入近128亿美元。</span></strong></span><span>Essilorluxottica正在寻求眼镜市场的进一步主导地位,今年夏天宣布,打算斥资数十亿美元收购Grandvision及其全球7200家眼镜店。</span></p><section data-tools="gulangu" data-id="95070"><section data-width="100%"><p><p><img src="image/20201014/7129bebb27fa92a0e39613a8b8e458e1_3.jpg" /></p></p><section><section powered-by="gulangu"><section></section></section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><p><strong>No.09</strong></p></section></section></section></section><section><section powered-by="gulangu"><p><strong>史赛克</strong></p></section></section></section><section powered-by="gulangu"><section><p><br  /></p><p>2018年收入:136亿美元</p><p>研发支出:86.2亿美元</p><p>员工:36000</p><p>员工平均收入:377778美元</p><p>财政年度结束:2018年12月31日</p><p>去年排名:10</p></section></section></section></section><section powered-by="gulangu"><section></section></section></section><section><br  /></section></section></section><p><strong><span>这家全球最大的骨科设备公司今年势头强劲,在2018年,其利润增长了两倍多,达到36亿美元,销售额增长了9.3%,达到136亿美元。</span></strong><span>史赛克高层认为,该公司整合了K2M,从而巩固了其在脊椎市场的地位,该公司于2018年11月以约14亿美元收购了K2M。</span><span>stryker的mako系统对机器人辅助膝关节和髋关节手术的需求也仍然很高。</span></p><p><br  /></p><p><span>史赛克分析师在3月份的aaos年会上写道,在不断扩大的品类中,mako仍然是同类中最好的。</span><span>史赛克本月宣布,将以5亿美元全现金竞购Mobius Imaging及其卡丹机器人子公司,进一步巩固其在机器人领域的早期地位。</span></p><p><br  /></p><p><p><img src="image/20201014/d30f03405fdb562727fbe02ffc1f91e3_4.jpg" /></p></p><section><section powered-by="gulangu"><section></section></section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><p><strong>No.08</strong></p></section></section></section></section><section><section powered-by="gulangu"><p><strong>丹纳赫</strong></p></section></section></section><section powered-by="gulangu"><section><p><br  /></p><p>2018年收入:155.74亿美元</p><p>财政年度结束:2018年12月31日</p><p>去年排名:8</p></section></section></section></section><section powered-by="gulangu"><section></section></section></section><p><br  /></p><p><span>丹纳赫销售业务主要分为由生命科学、诊断、环境与应用解决方案、牙科四大板块构成,其中生命科学和诊断业务占比较高。</span><span><strong><span>2018年丹纳赫实现营业收入198.93亿美元,同比增长8.53%。</span></strong></span><span>数据显示,在2014年出现一次负增长以后,丹纳赫营业收入保持较大幅度增长,2017开始增速放缓,为8.57%,2018年与其约为持平。</span></p><p><br  /></p><p><span>达纳赫仍有望在年底前将其牙科业务转变为一家名为envista的上市公司。</span><span>牙科业务生产牙科修复产品、正畸支架系统等。</span><span>同时也在推进其计划中的210亿美元收购通用生物制药。</span></p><p><span><br  /></span></p><p><p><img src="image/20201014/983a0f774fd51e44b096e618313661a8_5.jpg" /></p></p><section><section powered-by="gulangu"><section></section></section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><p><strong>No.07</strong></p></section></section></section></section><section><section powered-by="gulangu"><p><strong>Cardinal Health</strong></p></section></section></section><section powered-by="gulangu"><section><p><br  /></p><p>2018年收入:156.33亿美元</p><p>员工:49500</p><p>员工平均收入:315818美元</p><p>财政年度结束:2018年6月30日</p><p>去年排名:6</p></section></section></section></section><section powered-by="gulangu"><section></section></section></section><p><br  /></p><p><span>作为美国药械流通的三巨头之首、2018年全球医疗器械公司排名第6位、年收入130亿美元的康德乐,今年3月正式中国更新中文品牌名称“嘉德诺”。</span></p><p><br  /></p><p><span>Cardinal Health在医疗业务部分仍有很多工作要做。</span><span>在截至6月30日的公司最近一个财政年度,该部门的收入持平,利润下降。</span><strong><span>自Cardinal Health斥资19.4亿美元收购强生公司(Johnson&amp;Johnson)的Cordis以来,已有四年时间了,但该公司仍在努力应对与支架、气球和其他介入性心脏病产品制造商有关的挑战。</span></strong></p><p><br  /></p><p><span>首席执行官迈克考夫曼(mike kaufmann)在8月份的一次财报电话会议上称,cordis正走上盈利之路,理由是许多地区的业绩都出现了一线增长,填充率和缺货订单都有所改善。</span><strong><span>Cardinal Health最近为其医疗业务引入了一种新的销售结构,并正在进行一个漫长的过程,以转换其制造、供应链和数据能力。</span></strong></p><p><br  /></p><p><span>考夫曼说,目前的重点是围绕产品收购的执行与并购。</span><span>今年8月,该公司提拔曾任Cardinal Health at Home Solutions业务总裁的斯蒂芬?梅森(Stephen Mason)出任医疗部门首席执行官。</span></p><p><span><br  /></span></p><p><p><img src="image/20201014/c97d6254088b1d8c79b792ca08786a52_6.jpg" /></p></p><p><br  /><span></span></p><section><section powered-by="gulangu"><section></section></section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><p><strong>No.06</strong></p></section></section></section></section><section><section powered-by="gulangu"><p><strong>西门子医疗</strong></p></section></section></section><section powered-by="gulangu"><section><p><br  /></p><p>2018年收入:158.64亿美元</p><p>研发支出:15.14亿美元</p><p>员工:50000</p><p>员工平均收入:317286美元</p><p>财政年度结束:2018年7月30日</p><p>去年排名:7</p></section></section></section></section><section powered-by="gulangu"><section></section></section></section><p><br  /></p><p><span>西门子医疗公司是在外科机器人领域大展拳脚的医疗器械公司之一。</span><span><strong><span>今年8月,有消息称,该公司的西门子医疗解决方案子公司计划斥资11亿美元收购corindus vascular robotics,后者是FDA批准的corpath grx血管机器人系统的制造商。</span></strong></span><span>首席执行官马克?托兰(mark toland)当时表示,这笔交易将把公司的精密机器人技术与西门子healthineers的成像、数字和人工智能工具结合起来。</span><span></span></p><p><br  /></p><p><span>西门子医疗是医疗成像系统的主要制造商,包括计算机断层成像、核磁共振成像、分子成像、X射线和超声波。</span><span>该公司还生产用于图像引导治疗的血管造影系统、移动c臂和混合手术室,以及诊断测试系统,其他服务包括软件和临床咨询。</span><span>西门子集团2018财年年报显示,该公司的研发工作特别注重人工智能。</span><span>公司官员认为人工智能可以改进对医疗信息的处理,发现隐藏的模式,并做出更好地临床决策。</span><span>截至2018年9月30日的财年,西门子Healthineers的收入和利润略有下降。</span></p><p><p><img src="image/20201014/c385a3258403e9295fae5910377b3715_7.jpg" /></p></p><p><span></span></p><section><section powered-by="gulangu"><section></section></section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><p><strong>No.05</strong></p></section></section></section></section><section><section powered-by="gulangu"><p><strong>费森尤斯</strong></p></section></section></section><section powered-by="gulangu"><section><p><br  /></p><p>2018年收入:195.54亿美元</p><p>研发支出:1.58亿美元</p><p>员工:50000</p><p>员工平均收入:317286美元</p><p>财政年度结束:2018年12月31日</p><p>去年排名:3</p></section></section></section></section><section powered-by="gulangu"><section></section></section></section><p><br  /></p><p><span>费森尤斯医疗是慢性肾脏病护理领域全球最大的医疗设备公司,为全球30多万患者提供透析产品及服务。</span><span>该公司已成为全球透析市场的领导者。</span></p><p><br  /></p><p><span>有关费森尤斯最大地消息是,</span><strong><span>今年2月美国联邦贸易委员会批准德国费森尤斯和美国家庭透析设备制造商NxStage Medical Inc的合并。</span></strong><span>美国联邦贸易委员会表示,为了达成20亿美元交易的批准,两家公司同意出售NxStage的血管套装(bloodline tubing set)业务。</span><span></span></p><p><br  /></p><p><strong><span>2019年7月,由于特朗普政府计划彻底改革肾脏治疗市场,寻求降低联邦政府每年1000亿美元的肾脏护理费用的消息,该公司股票受到重创。</span></strong><span>该策略涉及美国卫生与公共服务部的新支付模式,旨在将患者从费森尤斯的血液透析诊所转移到自己的家中接受治疗;</span><span>卫生与公众服务部还计划增加肾脏疾病的预防和筛查。</span><span>2018年,费森尤斯净收入增长55%至19.8亿欧元,销售额下降7%至165.5亿欧元。</span></p><p><span><br  /></span></p><p><p><img src="image/20201014/26b2c4b66fc4292fd4b7af948a7c2b59_8.jpg" /></p></p><p><br  /><span></span></p><section><section powered-by="gulangu"><section></section></section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><p><strong>No.04</strong></p></section></section></section></section><section><section powered-by="gulangu"><p><strong>GE Healthcare</strong></p></section></section></section><section powered-by="gulangu"><section><p><br  /></p><p>2018年收入:197.84亿美元</p><p>财政年度结束:2018年12月31日</p><p>去年排名:5</p></section></section></section></section><section powered-by="gulangu"><section></section></section></section><p><br  /></p><p><span>GE医疗在经历了动荡的一年后,仍未独立上市。</span><span>在2018年6月宣布,它打算出售20%的股份,据说到明年1月,它将考虑进行更大规模的剥离,高达49.9%。</span></p><p><br  /></p><p><span>但在2月份,新任首席执行官拉里?卡尔普(larry culp)提出了医疗保健业务的分拆方案,以便这家工业集团能够专注于210亿美元的生物制药业务销售。</span><span>拉里?卡尔普曾于2018年10月受聘,负责设计一项扭亏为盈的方案。</span><span>今年6月,据说GE正在购买其风险投资组合,该组合包括医疗、科技和能源领域的100多家初创企业,希望控制其1100亿美元的债务负担。</span><span></span></p><p><br  /></p><p><strong><span>GE医疗2018年全年利润增长6.0%,至37.0亿美元,销售额增长4.0%,至197.8亿美元,</span></strong><span>而母公司全年亏损增长155.6%,至-228.0亿美元,销售额增长2.3%,至1135.4亿美元。</span></p><p><p><img src="image/20201014/7fa486cf93dc8f432509bb8f1274501a_9.jpg" /></p></p><p><span></span></p><section><section powered-by="gulangu"><section></section></section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><p><strong>No.03</strong></p></section></section></section></section><section><section powered-by="gulangu"><p><strong>飞利浦医疗</strong></p></section></section></section><section powered-by="gulangu"><section><p><br  /></p><p>2018年收入:214.14亿美元</p><p>研发支出:20.8亿美元</p><p>员工:77400</p><p>员工平均收入:317286美元</p><p>财政年度结束:2018年12月31日</p><p>去年排名:3</p></section></section></section></section><section powered-by="gulangu"><section></section></section></section><p><br  /></p><p><span>飞利浦医疗今年1月重组,将睡眠和呼吸部分从个人健康转移到新的互联医疗部门,并将医疗信息学转移到诊断和治疗部分。</span><span>在新的架构下,飞利浦有三个部门:</span><span>诊断与治疗部、联保部和个人健康部。</span><span></span></p><p><br  /></p><p><strong><span>2018年全年利润下降41.3%,至11.0亿欧元,或每股1.75欧元,销售额增长1.9%,至181.2亿欧元。</span></strong></p><p><br  /></p><p><span>今年年内,飞利浦医疗还进行了一些收购,收购了远程放射学平台开发商Direct Radiology、Carestream Health的成像IT业务、脉搏血氧传感器制造商Xhale Assurance和总部位于波士顿的患者导航平台Medumo,收购金额均未披露。</span><span></span></p><p><br  /></p><p><strong><span>在2019年6月,飞利浦在明尼苏达州罗切斯特开设了一个新的研发中心,以促进其与梅奥诊所的合作。</span></strong></p><p><p><img src="image/20201014/dd5adc0794efd1cf93a3dac60a0d6854_10.jpg" /></p></p><section><section powered-by="gulangu"><section></section></section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><p><strong>No.02</strong></p></section></section></section></section><section><section powered-by="gulangu"><p><strong>强生医疗</strong></p></section></section></section><section powered-by="gulangu"><section><p><br  /></p><p>2018年收入:269.94亿美元</p><p>研发支出:17.64亿美元</p><p>员工:77400</p><p>员工平均收入:317286美元</p><p>财政年度结束:2018年12月31日</p><p>去年排名:2</p></section></section></section></section><section powered-by="gulangu"><section></section></section></section><p><br  /></p><p><strong><span>2018年,强生医械业务269.64亿美元,增长放缓,营收同比+1.5%(2017年同比+5.6%)。</span></strong><span>心血管业务、眼科业务的双位数增长、外科手术业务的个位数增长被糖尿病护理业务高达37.5%的下滑所抵消。</span></p><p><br  /></p><p><span>强生医疗在这一年里进入了医疗技术最热门的领域之一,在Auris Health和其Monarch机器人辅助支气管镜检查平台上花费了34亿美元,用Verb Surgical和矫形外科来补充机器人辅助普外科计划,并且收购骨科平台。</span></p><p><br  /></p><p><span>强生投诉机器人技术先驱直觉外科,美国国际贸易委员会同意审查其投诉,称直觉的进口外科订书机墨盒侵犯了强生五项专利。</span></p><p><br  /></p><p><strong><span>强生继续重组医疗器械部门,进行了两项资产剥离:</span></strong><strong><span>以28亿美元的价格将其先进的消毒产品业务出售给Fortive,并以21亿美元的价格出售旗下的Lifecan血糖监测子公司Platinum Equity。</span></strong></p><p><br  /></p><p><span>据美国《法制新闻》报道,州检察长就骨盆网产品提起的第一次诉讼进入了庭审,指控其Ethicon子公司向公众和医生隐瞒了骨盆网产品的潜在风险。</span><span>四月,强生以1000万美元在华盛顿解决了类似的案件,肯塔基也在起诉Ethicon。</span><span><strong><span>而其Depuy Synthes子公司面临的大部分剩余金属对金属髋关节病例可能会以约10亿美元的价格得到解决。</span></strong></span></p><p><p><img src="image/20201014/d58549e6746ed850494c940dc503b2e7_11.jpg" /></p></p><section><section powered-by="gulangu"><section></section></section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><section><section powered-by="gulangu"><p><strong>No.01</strong></p></section></section></section></section><section><section powered-by="gulangu"><p><strong>美敦力</strong></p></section></section></section><section powered-by="gulangu"><section><p><br  /></p><p>2018年收入:305.57亿美元</p><p>研发支出:23.3亿美元</p><p>员工:90000</p><p>员工平均收入:339522美元</p><p>财政年度结束:2019年4月26日</p><p>去年排名:1</p></section></section></section></section><section powered-by="gulangu"><section></section></section></section><p><br  /></p><p><strong><span>今年,美敦力随着17亿美元收购马佐尔机器人公司(Mazor Robotics),该公司也大举进入整形外科机器人市场,并在财务方面简要介绍了该公司与直觉外科公司达芬奇(Da Vinci SP.)在机器人内外科领域展开竞争的计划。</span></strong><span><strong><span></span></strong></span></p><p><br  /></p><p><span>美敦力2019财年的利润超过普遍预期,增长49.2%至46.3亿美元,销售额增长2.0%至305.6亿美元。</span><span></span></p><p><br  /></p><p><span><strong><span>近期,美敦力发表了一份CEO继任计划,美敦力公司首席执行官Omar Ishrak将在经过近9年的掌舵后,在2020财年结束后退休。</span></strong></span><span><strong><span>由现任公司恢复治疗业务部门(RTG)总裁Geoff Martha,担任美敦力总裁新任职务。</span></strong></span></p><p><br  /></p><p><span>在Omar Ishrak8年的任期内,他的年收入翻了一番,为美敦力的市值增加了1000亿美元,并持续向全球市场和基于价值的医疗保健领域早期转变。</span><span>但最让人难忘的是收购——包括医疗器械行业史上最大规模的并购,美敦力在2015年初斥资500亿美元收购Covidien(柯惠)。</span><span></span></p><p><br  /></p><section data-role="outer" label="Powered by gulangu"><section data-role="paragraph" data-color="#757576"><section data-role="outer" label="Powered by gulangu"><section data-role="paragraph" data-color="#757576"><section data-role="outer" label="Powered by gulangu"><section data-role="paragraph" data-color="#757576"><section data-role="outer" label="Powered by gulangu"><section data-role="paragraph" data-color="#757576"><section data-role="outer" label="Powered by gulangu"><section data-role="paragraph" data-color="#757576"><section data-role="outer" label="Powered by gulangu"><section data-role="paragraph" data-color="#757576"><section data-role="outer" label="Powered by gulangu"><section data-role="paragraph" data-color="#757576"><section data-role="outer" label="Powered by gulangu"><section data-role="paragraph" data-color="#757576"><section data-role="outer" label="Powered by gulangu"><section data-role="paragraph" data-color="#757576"><section data-role="outer" label="Powered by gulangu"><section data-role="paragraph"><section><a data-miniprogram-appid="wxdc7efe409d688f37" data-miniprogram-path="pages/authorizationLogin/authorizationLogin" data-miniprogram-nickname="" href="" data-miniprogram-type="image" data-miniprogram-servicetype="" href=""><p><img src="image/20201014/2e25c809fffd6ef0866d70b58effc1a6_12.gif" /></p></a><br  /></section><section><br  /></section><section powered-by="gulangu"><section powered-by="gulangu"><section data-role="outer" label="Powered by gulangu"><section data-role="paragraph"><section><section><section data-brushtype="text"><strong>相关阅读</strong></section></section></section><section><section></section></section><section data-width="100%"><section><section><section><section data-width="100%"><section data-tools="gulangu" data-id="87578" data-color="#6aa9ad" data-custom="#59c3f9"><section><p><img src="image/20201014/2aac877ff9233ba5a66e7a5ff3a4febf_13.gif" /></p></section><section data-brushtype="text">戳一下,更有料!</section></section><section data-tools="gulangu" data-id="87578" data-color="#6aa9ad" data-custom="#59c3f9"><section data-brushtype="text"><br  /></section></section><section data-tools="gulangu" data-id="87578" data-color="#6aa9ad" data-custom="#59c3f9"><span>谁是最大黑马?——解析2018年全球医疗器械公司TOP10(附TOP100榜单)</span><br  /></section><section data-tools="gulangu" data-id="87578" data-color="#6aa9ad" data-custom="#59c3f9"><section data-brushtype="text"><br  /></section></section><section data-tools="gulangu" data-id="87578" data-color="#6aa9ad" data-custom="#59c3f9"></section><section data-tools="gulangu" data-id="87578" data-color="#6aa9ad" data-custom="#59c3f9"></section><section data-tools="gulangu" data-id="87578" data-color="#6aa9ad" data-custom="#59c3f9"></section><p><span>迈瑞持续领跑,理邦利润暴增,看55家医疗器械企业半年业绩大比拼</span><br  /></p><p><br  /></p><p><span>大数据看FDA之二十:</span><span>放射科Top50产品连线NMPA,医用成像独大</span><br  /></p><p><br  /></p><p><span>十张图解锁2019年医械行业竞争格局与发展趋势:</span><span>跨境并购提速,集中进程加快</span><br  /></p><p><br  /></p><p><span>全球骨科企业大数据发布,12家中国企业挺进百强!</span><br  /></p></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section><p><br  /></p><p><p><img src="image/20201014/aad9f56b0707b5374bbac6273a663447_14.jpg" /></p></p>
               
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

Archiver|手机版|小黑屋|Comsenz Inc. ( 浙ICP备17000336号-1 )

GMT+8, 2025-3-14 23:30 , Processed in 0.076820 second(s), 33 queries .

Powered by Discuz! X3.4

© 2001-2017 Comsenz Inc.

快速回复 返回顶部 返回列表